SD-101-6.0 cream

DRUG2 trials

Sponsors

Scioderm, Inc.

Conditions

Epidermolysis Bullosa

Phase 3

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

CompletedNCT02384460

Scioderm, Inc.Epidermolysis Bullosa

Start: 2015-03-11End: 2017-07-05Updated: 2020-04-09

Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

TerminatedNCT02670330

Scioderm, Inc.Epidermolysis Bullosa

Start: 2015-06-09End: 2018-09-03Updated: 2019-09-27

Related Papers

Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study.

2020-07-216 citations

Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study).

2020-06-2313 citations

Oleogel-S10 Phase 3 study "EASE" for epidermolysis bullosa: study design and rationale.

2019-06-1115 citations